Drug Trial Radar · NCT05072522
A Study of SKLB1028 in Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
98
Planned (sponsor's estimate)
Start
Oct 2021
Primary completion
Oct 2023
Study completion Oct 2023
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SKLB1028 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SKLB1028Drug
SKLB1028 capsules, oral, once daily in continuous 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Treatment Emergent Adverse Event (TEAE)Time frame: From the initiation of the first dose to 28 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.